September 2026 results: profit up 46%; Anupam Rasayan takes control

Revenue Growth 20pctPat Growth 25pctExceptional ItemNegative Operating CashflowResults View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.3%Reaction day

₹680.90

prior close

₹660.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.8%-3.5% vs sector

On the reaction day the stock moved 3.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.0

10m

+1.5

15m

-1.5

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.3pendingpending-0.8-3.5

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For the half year ended September 2026, consolidated revenue rose 32.6% to Rs 59,894.26 lakh and profit attributable to owners rose 45.6% to Rs 10,234.96 lakh. Results included a Rs 4,108.61 lakh exceptional gain. Standalone operating cash flow was negative Rs 790.30 lakh, while consolidated cash flow was positive Rs 3,569.38 lakh. Anupam Rasayan took 50.07% control as promoter on September 28. The auditor's review was unmodified.

Likely market impact

Revenue and profit growth supports the stock, but the exceptional gain and negative standalone cash flow weaken earnings quality.